GleamWall
中文EN

MYGN MYRIAD GENETICS INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 899923 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-2.6%
TTM net income YoY67.8%
TTM EPS YoY69.0%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR—

Margins

Gross margin68.3%
Operating margin-14.3%
Net margin-16.1%
FCF margin—
EBITDA margin-10.0%

Returns

ROE-40.2%
ROA-19.3%
ROIC (approx.)-28.9%
Asset turnover1.20x

Leverage & solvency

Liabilities / assets55.8%
Debt / equity0.45x
Current ratio1.98x
Interest coverage-6.90x

Cash quality & payout

Operating cash flow / net income0.15x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$824.50M$837.60M
Cost of revenue$247.90M$252.20M
Gross profit$576.60M$585.40M
R&D expense$106.80M$113.40M
SG&A expense$256.80M$275.90M
Operating income-$387.20M-$123.50M
Interest expense$10.50M$2.80M
Pretax income-$395.10M-$123.50M
Income tax-$29.20M$3.80M
Net income-$365.90M-$127.30M
EBITDA-$333.50M-$62.30M
EPS (basic)-3.95-1.41
EPS (diluted)-3.95-1.41
Weighted avg. shares (diluted)92.60M90.60M
Balance sheet
Cash & equivalents$149.60M$111.90M
Short-term investments—$0
Receivables$115.30M$121.20M
Inventory$30.60M$27.50M
Current assets$332.60M$298.00M
PP&E, net$114.00M$117.40M
Goodwill$51.60M$286.30M
Intangibles$153.40M$262.40M
Total assets$706.60M$1.03B
Current liabilities$133.80M$164.10M
Short-term debt—$0
Long-term debt$119.90M$39.60M
Total debt$119.90M$39.60M
Total liabilities$338.60M$326.50M
Shareholders' equity$368.00M$701.10M
Net debt-$29.70M-$72.30M
Shares outstanding93.50M91.30M
Cash flow statement
Operating cash flow$1.80M-$8.70M
Investing cash flow-$27.40M-$11.90M
Financing cash flow$64.20M-$7.40M
Depreciation & amortization$53.70M$61.20M
Stock-based compensation$35.20M$49.80M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.